

# Corporate Action Notice

(Other than for a Distribution)

Updated January 2024

Section 1: Issuer information (mandatory)				
Name of issuer	Pacific Edge Limited			
Class of Financial Product	Ordinary shares			
NZX ticker code	PEB			
ISIN (If unknown, check on NZX website)	NZPEBE0002S1			
Name of Registry	MUFG Pension & Market Services			
Type of corporate action (Please mark with an X in the relevant box/es)	Share Purchase Plan/retail offer	X	Renounceable Rights issue or Accelerated Offer	
	Capital reconstruction		Non-Renounceable Rights issue or Accelerated Offer	
	Call		Bonus issue	
	Placement	X		
Record Date	The Record Date for the share purchase plan is yet to be determined. It is currently anticipated that it will be in July/August. PEB will release a further Corporate Action Notice when this is determined.			
Ex Date (one business day before the Record Date)	The Ex Date for the share purchase plan is yet to be determined. It is currently anticipated that it will be in July/August. PEB will release a further Corporate Action Notice when this is determined.			
Currency	NZD			
External approvals required before offer can proceed on an unconditional basis?	Yes. The placement is conditional on PEB obtaining all necessary or desirable shareholder approvals, and all necessary regulatory approvals, to complete the placement. In addition, completion of the share purchase plan will be conditional on the placement becoming unconditional.			
Details of approvals required	PEB shareholder approval to the placement by ordinary resolution, under NZX Listing Rule 4.2.1 and, if applicable, NZX Listing Rule 5.2.1.			

	PEB will also seek a waiver from NZX Listing Rule 4.19.1 to permit allotment of shares under the placement after shareholder approval is obtained.
<b>Section 6: Share Purchase Plans/retail offer</b>	
Number of Equity Securities to be issued OR Maximum dollar amount of Equity Securities to be issued	\$5 million of new fully paid ordinary shares (subject to the ability for PEB to scale applications or accept oversubscriptions at its complete discretion).
Minimum application amount (if any)	N/A
Maximum application amount per Equity Security holder	\$50,000
Subscription price per Equity Security	The placement price of \$0.100 per ordinary share
Scaling reference date	The Record Date.
Closing Date	The Closing Date for the share purchase plan is yet to be determined. It is currently anticipated that it will be in July/August. PEB will release a further Corporate Action Notice when this is determined.
Allotment Date	The Allotment Date for the share purchase plan is yet to be determined. It is currently anticipated that it will be in August. PEB will release a further Corporate Action Notice when this is determined.
<b>Section 7: Placement</b>	
Number of Equity Securities to be issued	150,000,000 new fully paid ordinary shares, based on a \$15 million placement (with the ability for PEB to increase the size of the placement and, therefore, the number of shares to be issued under the placement, at its complete discretion).
Issue price per Equity Security	\$0.100 per ordinary share.
Maximum dollar amount of Equity Securities to be issued	\$15 million (with the ability for PEB to increase the size of the placement, at its discretion).
Proposed issue date	The issue date for the placement is yet to be determined, as the date for obtaining shareholder approval is currently unknown. It is currently anticipated that the issue date will be in August. PEB will release a further Corporate Action Notice when this is determined.
Existing holders eligible to participate	Yes
Related Parties eligible to participate	Yes
Basis upon which participation by existing Equity Security holders will be determined	By reference to shareholdings on 29 May 2025.



Purpose(s) for which the Issuer is issuing the Equity Securities	Raise capital to ensure the company has the resources and capacity to capitalise on its recent clinical and commercial milestones, grow into non-Medicare channels and regain Medicare coverage.
Reason for placement rather than a pro-rata rights issue or an offer under a Share Purchase Plan in which the Issuer's existing Equity Security holders would have been eligible to participate	PEB considers a placement structure to be in the best interests of PEB and its existing shareholders, as the placement will allow PEB to access a broader pool of potential investors, provide greater certainty around the achievement of the targeted raising size and more favourable pricing for PEB. A Share Purchase Plan is intended to be offered in conjunction with the Placement.
Equity Securities to be issued subject to voluntary escrow	No
Number and class of Equity Securities to be issued that will be subject to voluntary escrow and the date from which they will cease to be escrowed	N/A
<b>Section 8: Lead Manager and Underwriter (mandatory)</b>	
Lead Manager(s) appointed	No
Name of Lead Manager(s)	N/A
Fees, commission or other consideration payable to Lead Manager(s) for acting as lead manager(s)	N/A
Underwritten	No
Name of Underwriter(s)	N/A
Extent of underwriting (i.e. amount or proportion of the offer that is underwritten)	N/A
Fees, commission or other consideration payable to Underwriter(s) for acting as underwriter(s)	N/A
Summary of significant events that could lead to the underwriting being terminated	N/A
<b>Section 9: Authority for this announcement (mandatory)</b>	
Name of person authorised to make this announcement	Grant Gibson
Contact person for this announcement	Grant Gibson
Contact phone number	+64 275 999 943
Contact email address	grant.gibson@pelnz.com
Date of release through MAP	29 May 2025

